SCHEMBL5261643

SCHEMBL5261643

Nc1ccc(S(=O)(=O)CCN2CCOCC2)cc1

nearest known ligand 0.72

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.72
MEN1 O00255 1/20 0.72
EPHX2 P34913 2/20 0.50
CA1 P00915 3/20 0.49
CA2 P00918 3/20 0.49
CA9 Q16790 3/20 0.49
CA12 O43570 1/20 0.49
CA7 P43166 1/20 0.49
LOX P28300 2/20 0.48
HRH3 Q9Y5N1 1/20 0.48
MAPT P10636 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
GAA P10253 2/20 0.46
CD274 Q9NZQ7 1/20 0.46
ALDH1A1 P00352 1/20 0.46
POLB P06746 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11531653 0.84 MEN1 (0.72) KMT2AMEN1EPHX2ALDH1A1POLB
SCHEMBL2920100 0.84 MEN1 (0.72) KMT2AMEN1EPHX2CA1CA2
SCHEMBL3517085 0.84 KMT2A (0.72) KMT2AMEN1EPHX2MAPTNPSR1
SCHEMBL1939359 0.84 KMT2A (0.72) KMT2AMEN1EPHX2MAPTNPSR1
SCHEMBL11535141 0.84 MEN1 (0.72) KMT2AMEN1EPHX2MAPTNPSR1
SCHEMBL56319 0.84 LOX (0.57) KMT2AMEN1LOXHRH3GAA
SCHEMBL12015818 0.84 KMT2A (0.67) KMT2AMEN1EPHX2MAPTNPSR1
SCHEMBL7798812 0.83 LMNA (0.51) KMT2AMEN1CA1CA2CA9
Hydrochloric Acid SCHEMBL11529235 0.83 KMT2A (0.97) KMT2AMEN1EPHX2MAPTNPSR1
SCHEMBL13408045 0.82 MEN1 (0.69) KMT2AMEN1EPHX2CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230133132-A1 NAMPT MODULATORS CYTOKINETICS, INC. 2023-05-04 US disclosed
EP-1272477-B1 PYRIMIDINE COMPOUNDS ASTRAZENECA AB (SE) 2007-05-09 EP disclosed
US-7153964-B2 Pyrimidine compounds ASTRAZENECA AB (SE) 2006-12-26 US disclosed
US-20030149064-A1 Pyrimidine compounds ASTRAZENECA AB (SE) 2003-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230133132-A1 NAMPT MODULATORS NAMPT, MC4R, SIRT1 KMT2A 1669/4885MEN1 484/4885EPHX2 4344/4885
US-20030149064-A1 Pyrimidine compounds CDK2, CCNI, CCNY KMT2A 227/4885MEN1 3100/4885EPHX2 1134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.